Abstract
Hypertension is one of the world’s largest public health problems and it is both a disease and a risk factor for cardiovascular disease (CVD). The heart, the endothelium and the kidneys are the target organs of hypertension. Recently, several antihypertensive drugs have been introduced to the market; therefore, the choice is mainly determined by the patients’ features. In particular, ACE inhibitors and angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]) demonstrate a larger reduction in cardiovascular risk than other antihypertensive treatments because of the existence of blood pressure-independent effects. In fact, the angiotensin II pathway plays a major role in metabolic, haemodynamic and endothelial homeostasis. For these reasons, ACE inhibitors and ARBs have primary indications in patients with obesity, hypercholesterolaemia and diabetes mellitus because of their favourable metabolic properties. Furthermore, several large trials have demonstrated that they have favourable effects also in patients with left ventricular dysfunction or systolic heart failure, as well as other forms of heart disease. Drugs affecting the angiotensin II pathway may reduce endothelial dysfunction through several mechanisms including reduction of vascular permeability and oxidative stress. Another important effect of these drugs is neuroprotection. This is an important effect because in the near future, due to an aging population, an important goal for optimal antihypertensive treatment will be the prevention of cognitive decline. ACE inhibitors and ARBs are very important drugs in the modern management of the total cardiovascular risk in hypertensive patients.
Similar content being viewed by others
References
World Health Organization. Quantifying selected major risks to health. In: The world health report 2002: reducing risks, promoting healthy life. Geneva: WHO, 2002 [online]. Available from URL: www.who.int/whr/2002/chapter4/en/print.html [Accessed 2008 Nov 4]
Staffileno BA. Treating hypertension with cardioprotective therapies: the role of ACE inhibitors, ARBs, and beta-blockers. J Cardiovasc Nurs 2005 Sep-Oct; 20(5): 354–64
Leenen FH. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome. Can J Cardiol 2004 Aug; 20Suppl. B: 77B–82B
Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25: 951–8
Sleight P. No HOPE without proof: do ARBs meet the standard for cardiovascular protection? Medscape J Med 2008; 10Suppl.: 96
Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–53
Weir MR. Risk-based classification of hypertension and the role of combination therapy. J Clin Hypertens (Greenwich) 2008 Jan; 10(1 Suppl. 1): 4–12
Sharma AM. Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension 2004 Jul; 44(1): 12–9
Sharma AM, Engeli S. The role of renin-angiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome. J Cardiometab Syndr 2006 winter; 1(1): 29–35
Segura J, Ruilope LM. Obesity, essential hypertension and renin-angiotensin system. Public Health Nutr 2007 Oct; 10(10A): 1151–5
Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000; 13: 3S–10S
Ginsberg HN, Stalenhoef AF. The metabolic syndrome: targeting dyslipidaemia to reduce coronary risk. J Cardiovasc Risk 2003; 10: 121–8
Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005; 111: 3481–8
Ferrario CM, Smith R, Levy P, et al. The hypertension-lipid connection: insights into the relation between angiotensin II and cholesterol in atherogenesis. Am J Med Sci 2002; 323: 17–24
Diet F, Pratt RE, Berry GJ, et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996; 94: 2756–67
Fukuhara M, Geary RL, Diz DI, et al. Angiotensin-converting enzyme expression in human carotid artery atherosclerosis. Hypertension 2000; 35: 353–9
Makaritsis KP, Gavras H, Du Y, et al. 1-Adrenergic plus angiotensin receptor blockade reduces atherosclerosis in apolipoprotein E-deficient mice. Hypertension 1998; 32: 1044–8
Schuh JR, Blehm DJ, Friedrich GE, et al. Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. J Clin Invest 1993; 91: 1453–8
Nickenig G, Sachinidis A, Michaelsen F, et al. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997; 95v: 473–8
Li D, Saldeen T, Romeo F, et al. Oxidized LDL upregulates angiotensin II type 1 receptor expression in cultured human coronary artery endothelial cells: the potential role of transcription factor NF-kappaB. Circulation 2000; 102: 1970–6
Nickenig G, Harrison DG. The AT1-type angiotensin receptor in oxidative stress and atherogenesis, part II: AT1 receptor regulation. Circulation 2002; 105: 530–6
Daugherty A, Rateri DL, Lu H, et al. Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation 2004; 110: 3849–57
Morawietz H. Beyond blood pressure: endothelial protection against hypercholesterolemia by angiotensin II type-1 receptor blockade. Hypertension 2005; 45: 185–6
Morawietz H, Erbs S, Holtz J, et al. Endothelial protection, AT1 blockade and cholesterol-dependent oxidative stress. Circulation 2006; 114: I–296–I–301
Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 2003; 24: 471–8
Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840–4
Morawietz H, Rueckschloss U, Niemann B, et al. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation 1999; 100: 899–902
Li DY, Zhang YC, Philips MI, et al. Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circ Res 1999; 84: 1043–9
Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 2004; 64(22): 2537–65
Benndorf RA, Rudolph T, Appel D, et al. Telmisartan improves insulin sensitivity in non-diabetic patients with essential hypertension. Metabolism 2006 Sep; 55(9): 1159–64
Mori Y, Itoh Y, Tajima N. Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes. Adv Ther 2007 Jan-Feb; 24(1): 146–53
Usui I, Fujisaka S, Yamazaki K, et al. Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. Diabetes Res Clin Pract 2007 Aug; 77(2): 210–4
Derosa G, Fogari E, D’Angelo A, et al. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther 2007 Jun; 32(3): 261–8
Galle J, Schwedhelm E, Pinnetti S, et al. on behalf of the VIVALDI investigators. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 2008; 23(10): 3174–83
Murray CJL, Lopez AD, editors. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Boston (MA): Harvard School of Public Health, 1996
Prisant LM. Management of hypertension in patients with cardiac disease: use of renin-angiotensin blocking agents. Am J Med 2008 Aug; 121(8 Suppl.): S8–15
The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429–35
McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767–71
Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection function: the CHARM-Preserved trial. Lancet 2003; 362: 777–81
Ertl G, Hu K. Anti-ischemic potential of drugs related to the renin-angiotensin system. J Cardiovasc Pharmacol 2001 Apr; 37Suppl. 1: S11–20
Hammoud RA, Vaccari CS, Nagamia SH, et al. Regulation of the renin-angiotensin system in coronary atherosclerosis: a review of the literature. Vasc Health Risk Manag 2007 Dec; 3(6): 937–45
Fox KM. European trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–8
Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention for Endpoint reduction in Hypertension (LIFE) study. Circulation 2003; 108: 684–90
Schrader J, Lüders S, Kulschewski A. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention. Stroke 2005; 36: 1218–24
Yusuf S, Sleight P, Anderson C, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59
Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–906
de Denus S, Zakrzewski-Jakubiak M, Dube MP, et al. Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan. Ann Pharmacother 2008 Jul; 42(7): 925–32
Biegelsen ES, Loscalzo J. Endothelial function and atherosclerosis. Coron Artery Dis 1999; 10: 241–56
De Meyer GR, Herman AG. Vascular and endothelial dysfunction. Prog Cardiovasc Dis 1997; 39: 325–42
Negro R. Endothelial effects of antihypertensive treatment: focus on irbesartan. Vasc Health Risk Manag 2008 Feb; 4(1): 89–101
Boger RH, Bode-Boger SM, Tsao PS, et al. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 2000; 36: 2287–95
De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. J Clin Invest 1995; 96: 60–8
Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leucocyte adhesion. Proc Natl Acad Sci USA 1991; 88: 4651–5
Radomski MW, Palmer RMJ, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987; II: 1057–68
Panza JA, Casino PR, Badar DM, et al. Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation 1993; 87: 1475–81
Campbell DJ. Circulating and tissue angiotensin systems. J Clin Invest 1987; 79: 1–6
Tamarat R, Silvestre JS, Durie M, et al. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor and inflammation-related pathways. Lab Invest 2002; 82: 747–56
Piqueras L, Kubes P, Alvarez A, et al. Angiotensin II induces leukocyte-endothelial cell interactions in vivo via AT(1) and AT(2) receptor-mediated P-selectin upregulation. Circulation 2000; 102: 2118–23
Pueyo ME, Gonzalez W, Nicoletti A, et al. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000; 20: 645–51
Pastore L, Tessitore A, Martinetti S, et al. Angiotensin II stimulates intracellular adhesion molecole-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 1999; 100: 1646–52
Persson F, Rossing P, Hovind P, et al. Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. Diabetes 2006; 55: 3550–5
Candido R, Allen TJ, Lassila M, et al. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation 2004; 109: 1536–42
Bragulat E, Larousse M, Coca A, et al. Effect of long-term irbesartan treatment on endothelium-dependent vasodilation in essential hypertensive patients. Br J Biomed Sci 2003; 60: 191–6
Makris TK, Stavroulakis GA, Krespi PG, et al. Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. Am J Hypertens 2000; 13: 783–8
Yao EH, Fukuda N, Matsumoto T. Losartan improves the impaired function of endothelial progenitor cells in hypertension via an antioxidant effect. Hypertens Res 2007 Nov; 30(11): 1119–28
Stumpe KO, Agabiti-Rosei E, Zielinski T, et al. Original research: carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Ther Adv Cardiovasc Dis 2007; 1: 97–106
Peralta CA, Kurella M, Lo JC, et al. The metabolic syndrome and chronic kidney disease. Curr Opin Nephrol Hypertens 2006; 15: 361–5
Segura J, Campo C, Gil P, et al. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 2004; 15: 1616–22
Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991; 121: 1244–63
Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens 2005; 23Suppl. 1: S9–S17
Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137–47
Becker GJ, Hewitson TD. The role of tubulointerstitial injury in chronic renal failure. Curr Opin Nephrol Hypertens 2000; 9: 133–8
Ghiadoni L, Cupisti A, Huang Y, et al. Endothelial dysfunction and oxidative stress in chronic renal failure. J Nephrol 2004; 17: 512–9
Osto E, Coppolino G, Volpe M, et al. Restoring the dysfunctional endothelium. Curr Pharm Des 2007; 13: 1053–68
Bernadet-Monrozies P, Rostaing L, Kamar N, et al. The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure. Presse Med 2002 Nov 9; 31(36): 1714–20
Vogt L, Kocks MJ, Laverman GD, et al. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease: specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance? Minerva Med 2004 Oct; 95 (5): 395–409
De Leeuw PW, Thijs L, Birkenhager WH, et al. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. J Am Soc Nephrol 2002; 13: 2213–22
Palmer BF. Management of hypertension in patients with chronic kidney disease and diabetes mellitus. Am J Med 2008 Aug; 121(8 Suppl.): S16–22
Wilms H, Rosenstiel P, Unger T, et al. Neuroprotection with angiotensin receptor antagonists: a review of the evidence and potential mechanisms. Am J Cardiovasc Drugs 2005; 5(4): 245–53
Rosenstiel P, Gallinat S, Arlt A, et al. Angiotensin AT2 receptor ligands: do they have potential as future treatments for neurological disease? CNS Drugs 2002; 16(3): 145–53
Acknowledgements
No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cipollone, F., Di Fabio, S., Bucci, M. et al. Angiotensin II Blockade and Total Cardiovascular Risk. High Blood Press Cardiovasc Prev 15, 245–253 (2008). https://doi.org/10.2165/0151642-200815040-00004
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2165/0151642-200815040-00004